查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837436

肝腎綜合症治療市場（按產品類型、給藥途徑、患者嚴重程度和最終用戶分類）—2025-2032 年全球預測

Hepatorenal Syndrome Treatment Market by Product Type, Route Of Administration, Patient Severity, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝腎症候群治療市場將成長至 74.5 億美元，複合年成長率為 5.64%。

主要市場統計數據
基準年2024年 48億美元
預計2025年 50.7億美元
預測年份：2032年 74.5億美元
複合年成長率（%） 5.64%

簡明的策略入門指南，概述了當今肝腎症候群治療的臨床複雜性、相關人員的優先事項和決策要求

肝腎症候群是一種複雜的疾病，其特徵是肝功能衰竭和進行性性腎功能障礙相互作用，需要臨床、付款方和商業層面的協調應對。本執行摘要旨在提供一份簡明的策略性入門指南，綜合當今影響治療方法的臨床進展、治療定位和商業性需求。本摘要重點在於影響臨床決策和相關人員獎勵的促進因素，旨在為高階主管提供做出明智投資和合作決策所需的背景資訊。

隨著多學科團隊努力在短期腎臟支持和長期肝臟穩定之間取得平衡，肝腎症候群的臨床管理也不斷演變。除了程序性介入之外，人們重新關注調節腎臟灌注和全身性血流動力學的藥物策略。因此，臨床醫生、健康系統和專科組織正在重新調整患者治療路徑，優先考慮早期發現和分層治療，而支付方也在重新評估覆蓋框架，以反映臨床效益和資源利用率。本介紹對這種轉變模式進行了更深入的分析，並為產業領導者提供了行動建議。

新的臨床分層、現代化的醫療保健服務和價值主導的獎勵正在重塑肝腎症候群的治療決策途徑

由於臨床創新、醫療服務模式的變革以及監管預期的不斷變化，肝腎症候群的治療格局正在發生重大變化。近期的臨床實務使得患者分層更加精細，因此可以採取差異化的治療途徑，而非千篇一律的治療方案。同時，支持性治療和血流動力學管理的進展正在改變患者的短期預後，並促使臨床醫生重新考慮何時以及如何實施疾病修正治療。

隨著臨床治療的不斷發展，支付模式和醫院營運重點也在獎勵基於價值的醫療服務，這種服務強調展示臨床效用、縮短住院時間和降低再入院率。製劑和給藥途徑的創新使得該服務在從重症住院治療到門診和居家護理等各種醫療環境中得到更廣泛的應用。這些變化共同為研發者、醫療服務提供者和支付方創造了機會，也賦予了他們義務，促使他們合作制定證據生成和實施策略，將臨床潛力轉化為患者和醫療系統的可衡量效益。

貿易政策和關稅的變化正在推動整個肝腎症候群治療價值鏈的策略性供應鏈調整和採購彈性措施。

近期政策週期中推出的新關稅政策和貿易措施，為透過國際供應鏈採購活性成分、製劑和成品的企業帶來了策略上的複雜性。依賴跨境採購的企業被迫實現供應商、庫存策略和定價的多元化，以減輕進口成本上漲的影響。為此，一些企業加快了近岸外包或合格的替代供應商，以保持供應的連續性和利潤的穩定性。

監管和清關程序也已成為上市時間和分銷規劃中更關鍵的因素。因此，商業化時間表現在通常包含關稅情境分析和應急計劃，以確保關鍵市場的產品供應。營運團隊優先考慮合約彈性和包含風險共擔框架的長期供應商關係。這些調整也對採購、法務和商務部門產生了廣泛的影響，這些部門必須緊密合作，在保障財務表現的同時，維持治療藥物的可預測性。

策略性地調整產品定位、交付形式、患者風險狀況和護理環境，以最佳化肝病治療的臨床應用和商業性影響

細分分析揭示了產品類型、給藥途徑、患者病情和最終用戶環境等方面的不同策略考量，這些因素會影響臨床定位和商業性執行。透過產品類型區分品牌學名藥，我們發現品牌藥往往注重臨床差異化、臨床試驗證據和溢價策略，而學名藥主要在成本和可及性方面展開競爭，從而影響處方動態和處方行為。就給藥途徑而言，靜脈注射的區別決定了操作流程，靜脈注射通常更適合急性住院患者，而口服給藥則更適合門診病人管理，甚至可能居家照護。

I 型和 II 型患者的病情嚴重程度細分需要臨床方案和價值敘述的協調，因為 I 型患者通常需要更密集的干涉和快速的血流動力學穩定，而 II 型患者可能受益於更長期的最佳化策略。最後，居家醫療機構、醫院和專科診所的終端使用者細分直接影響分銷、病患監測要求和支援服務。這些細分維度相互影響，形成獎勵，決定了臨床採用模式、相關人員以及製造商和服務供應商在其上市計劃中必須考慮的商業性優先事項。

協調的區域策略和本地證據產生對於應對全球監管多樣性、報銷差異和採用途徑至關重要

區域動態對藥品法規、報銷模式、臨床實踐和供應鏈有著重大影響，因此了解這些差異對於制定市場准入和商業化策略至關重要。在美洲，臨床研究環境和支付系統差異巨大，需要製定細緻入微的合作計劃，以應對公共和私人承保流程，並優先考慮真實世界證據的生成，以支持處方可及性。在歐洲、中東和非洲，監管協調工作與國家層面的顯著差異並存，許可策略和衛生技術評估應用必須根據該地區的證據和經濟閾值進行客製化。

在亞太地區，創新醫療模式正在一些市場迅速普及，但由於各國基礎設施和採購慣例的巨大差異，這一進程並不均衡。與區域利害關係人建立策略相關人員夥伴關係並投資於當地臨床教育，可以在產能允許的情況下加速採用；而在其他地區，成本敏感的採購環境則需要採取其他可及策略。為了確保患者在不同地區永續獲得醫療服務，製造商應根據當地的醫療實踐模式和報銷情況，量身定做臨床開發、定價和分銷計劃。

競爭差異化源自於基於臨床證據的肝病治療策略、製造敏捷性以及促進採用和可擴展性的夥伴關係模式

肝腎症候群治療生態系統中的關鍵參與者在戰略重點上各不相同，從專注於新型血流動力學和腎灌注藥物的開發商，到最佳化製劑和給藥平台以提高整個治療領域可用性的公司。一些公司透過有針對性的臨床計畫和真實世界試驗來強調臨床差異化，而另一些公司則透過注重成本效益的生產和供應鏈彈性來優先考慮廣泛的可及性。專科藥物開發商、契約製造和醫療保健提供者之間的合作對於縮短開發週期並確保腸外和口服製劑生產的可擴展性變得越來越重要。

策略聯盟和授權協議是擴大地域覆蓋範圍和共用開發風險的常見手段。積極投資核准後觀察性研究和與專業協會合作的教育計畫的公司，能夠影響臨床指南和處方實踐。此外，將患者支援服務和數位監控功能整合到產品中的公司，可以透過提高依從性並促進住院和門診護理的連續性，提供差異化的價值提案。

透過以證據為導向的開發、供應鏈應急計畫和分段商業化策略，提供以行動為導向的指導，以加速採用和復原能力

為了抓住肝腎症候群治療領域的機遇，產業領導者應優先考慮一種整合方法，將臨床證據產生、供應鏈韌性和相關人員參與相結合。首先，臨床開發應優先考慮能引起臨床醫生、付款方和監管機構共鳴的終點，以促進更快的採用和報銷討論。這包括設計反映真實世界治療途徑的實用性試驗，並展示對醫療保健系統重要的結果，例如降低加護病房的使用率和改善腎功能軌跡。

其次，供應鏈和籌資策略應針對地緣政治和關稅相關情境進行壓力測試，並制定針對替代供應商、近岸外包選項和庫存緩衝的應急計畫。第三，商業策略應反映細分市場的優先事項，例如協調品牌和非專利的定位，突顯相關靜脈注射或口服製劑的營運優勢，並滿足I類和II類患者群體的不同需求。最後，與醫院、專科診所和居家照護機構建立夥伴關係，並整合支援服務和數位監控，可以提高護理的依從性和連續性，從而強化支付方和提供者雙方的價值提案。

結合臨床醫師意見、監管調查和供應鏈訪談的嚴格、多源質性調查方法，為相關人員提供可行的策略見解

本分析所採用的調查方法結合了跨部門證據綜合分析，旨在捕捉臨床實務、相關人員和營運現狀的變化​​。主要資訊包括獎勵執業肝病專家、腎臟科醫師、醫院藥師和專科診所管理人員，以檢驗實際的實務途徑和應用障礙。補充資訊包括對同儕審查臨床文獻、臨床試驗註冊中心和監管指導文件的系統性綜述，以檢驗治療趨勢和不斷發展的護理標準。

營運洞察源自於對供應鏈和採購專家的訪談，以及對已發布的政策公告和貿易指南的審查，旨在了解關稅和採購變化的影響。在適當的情況下，調查方法著重於質性綜合和情境分析而非定量預測，以確保研究結果適用於不同的市場環境。調查團隊也進行了嚴格的資訊來源檢驗和相關人員交叉核對，以確保可行的洞察能夠反映當前的臨床和商業現實。

結論摘要強調了綜合證據、營運彈性和有針對性的參與，以將臨床進展轉化為永續的患者可及性

總而言之，有效駕馭肝腎綜合症治療格局需要整合策略，將臨床差異化、營運韌性和市場導向的參與度相結合。臨床進展和不斷發展的護理模式為改善患者預後提供了機會，但要實現這些益處，需要製定與臨床醫生和付款人溝通的循證策略，以及確保藥物可及性連續性的供應鏈決策。能夠預見區域和政策差異的公司將能夠更好地制定符合當地實踐和報銷現實的、具有韌性的商業化計劃。

要從洞察轉化為影響力，需要對有針對性的臨床計畫進行重點投資，與醫院和門診機構的醫療服務提供者合作，並積極主動地管理採購風險。透過強調可衡量的臨床效益以及切實可行的應用考量，相關人員可以建立一個令人信服的價值提案，以支持永續的可及性，並最終改善肝腎症候群患者的照護途徑。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 肝腎症候群早期檢測的非侵入性生物標記研究進展
  • 特利加壓素在改善進行性肝腎症候群患者存活率的新作用
  • 整合人工智慧演算法預測肝腎症候群的發病及結局
  • 選擇性內皮素受體拮抗劑治療HRS腎功能不全的臨床評價
  • 擴大採用白蛋白輸注通訊協定來預防肝硬化相關腹水穿刺術中的腎衰竭
  • 擴大血管加壓藥物治療第1型肝腎症候群的真實世界證據研究
  • 肝腎疾病患者腎臟血流動力學監測的超音波創新
  • 不斷變化的監管格局和新型 HRS 療法的快速核准途徑推動了市場發展勢頭

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章肝腎綜合症治療市場（依產品類型）

  • 品牌
  • 非專利的

9. 肝腎綜合症治療市場（依給藥途徑）

  • 靜脈
  • 口服

第 10 章肝腎症候群治療市場（依患者嚴重程度）

  • I型
  • II型

第11章肝腎症候群治療市場（依最終用戶）

  • 居家照護環境
  • 醫院
  • 專科診所

第12章肝腎症候群治療市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章肝腎症候群治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章肝腎症候群治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Mallinckrodt Pharmaceuticals plc
    • Ferring Pharmaceuticals A/S
    • Baxter International Inc.
    • Grifols, SA
    • Octapharma AG
    • CSL Limited
    • Kedrion SpA
    • LFB Group
    • B. Braun Melsungen AG
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-035DA3C63700

The Hepatorenal Syndrome Treatment Market is projected to grow by USD 7.45 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.80 billion
Estimated Year [2025] USD 5.07 billion
Forecast Year [2032] USD 7.45 billion
CAGR (%) 5.64%

A concise strategic primer outlining clinical complexities, stakeholder priorities, and decision-making imperatives shaping hepatorenal syndrome treatment today

Hepatorenal syndrome presents a complex intersection of hepatic failure and progressive renal dysfunction that demands coordinated clinical, payer, and commercial responses. The intent of this executive summary is to provide a concise, strategic primer that synthesizes clinical advances, therapeutic positioning, and commercial imperatives influencing treatment approaches today. By focusing on drivers that shape clinical decision-making and stakeholder incentives, the narrative aims to equip executives with the context required to make informed investments and partnership decisions.

Clinical management of hepatorenal syndrome continues to evolve as multidisciplinary teams strive to balance short-term renal support with long-term hepatic stabilization. Beyond procedural interventions, pharmacologic strategies that modulate renal perfusion and systemic hemodynamics are receiving renewed attention. Consequently, clinicians, health systems, and specialty providers are recalibrating patient pathways to prioritize early detection and stratified treatment, and payers are reassessing coverage frameworks to reflect both clinical benefit and resource utilization. This introduction sets the stage for a deeper analysis of shifting paradigms and recommended actions for industry leaders.

Emerging clinical stratification, care delivery modernization, and value-driven incentives are reshaping therapeutic decision pathways for hepatorenal syndrome

The landscape of hepatorenal syndrome treatment is undergoing transformative shifts driven by clinical innovation, changes in care delivery, and evolving regulatory expectations. Recent clinical practice has moved toward more nuanced patient stratification, which enables differentiated therapeutic pathways rather than a one-size-fits-all approach. At the same time, advances in supportive care and hemodynamic management have altered short-term outcomes, prompting clinicians to reassess when and how to deploy disease-modifying therapies.

Parallel to clinical evolution, payment models and hospital operational priorities are incentivizing value-based care, which places a premium on demonstrable clinical benefit, reduced length of stay, and fewer readmissions. Innovations in formulations and routes of administration are enabling broader applicability across care settings, from intensive inpatient care to outpatient and home-based options. Taken together, these shifts create both opportunities and responsibilities for developers, providers, and payers to collaborate on evidence generation and implementation strategies that translate clinical promise into measurable patient and system benefit.

Trade policy shifts and tariff changes are prompting strategic supply chain realignment and procurement resilience measures across the hepatorenal syndrome treatment value chain

The introduction of new tariff policies and trade measures in recent policy cycles has introduced a strategic layer of complexity for companies that source active ingredients, formulations, and finished products through international supply chains. Firms that depend on cross-border procurement have been compelled to reassess supplier diversification, inventory strategies, and pricing structures to mitigate the impact of increased import costs. In response, some organizations have accelerated nearshoring initiatives or qualified alternative suppliers to preserve continuity of supply and margin stability.

Regulatory compliance and customs processes have also become a more prominent factor in launch timing and distribution planning. As a result, commercialization timelines now routinely integrate tariff scenario analyses and contingency plans to ensure product availability in key markets. Operational teams are prioritizing contractual flexibility and longer-term supplier relationships that incorporate shared risk frameworks. These adjustments have broader implications for procurement, legal, and commercial functions, which must coordinate closely to maintain predictable access to therapies while protecting financial performance.

Strategically aligning product positioning, delivery modality, patient risk profiles, and care settings to optimize clinical adoption and commercial impact in hepatorenal therapy

Segmentation analysis reveals distinct strategic considerations across product type, route of administration, patient severity, and end-user settings that influence clinical positioning and commercial execution. When differentiating by product type between branded and generic options, branded therapies tend to focus on clinical differentiation, targeted clinical trial evidence, and premium pricing strategies, whereas generic entrants compete primarily on cost and accessibility, influencing formulary dynamics and prescribing behavior. Considering route of administration, the distinction between intravenous and oral delivery shapes operational workflows, with intravenous therapies typically favored in acute inpatient settings and oral options enabling outpatient management and potential home-based care pathways.

Patient severity segmentation between Type I and Type II patients necessitates tailored clinical protocols and value narratives, as Type I patients often require more intensive intervention and rapid hemodynamic stabilization, whereas Type II patients may benefit from longer-term optimization strategies. Finally, end-user segmentation across home care settings, hospitals, and specialty clinics directly affects distribution, patient monitoring requirements, and support services. Each of these segmentation dimensions interacts, creating combinations that determine clinical adoption patterns, stakeholder incentives, and commercial priorities that manufacturers and service providers must address in their go-to-market planning.

Calibrated regional strategies and localized evidence generation are essential to navigate regulatory diversity, reimbursement variability, and adoption pathways globally

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement models, clinical practice, and supply chain considerations, and understanding these variations is essential for tailoring market entry and commercialization strategies. In the Americas, clinical research environments and payer systems vary widely, requiring nuanced engagement plans that address both public and private coverage processes and prioritize real-world evidence generation to support formulary access. Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant country-level heterogeneity, which means licensing strategies and health technology assessment submissions must be customized to local evidentiary and economic thresholds.

In the Asia-Pacific region, rapid adoption of innovative care models in some markets is balanced by significant differences in infrastructure and procurement practices across countries. Strategic partnerships with regional stakeholders and investments in local clinical education can accelerate adoption where capacity allows, while cost-sensitive procurement environments necessitate alternative access strategies in other jurisdictions. Across all regions, manufacturers should calibrate their clinical development, pricing, and distribution plans to reflect local practice patterns and reimbursement realities to ensure sustainable patient access.

Competitive differentiation emerges through clinical evidence strategies, manufacturing agility, and partnership models that drive adoption and scalability in hepatorenal treatments

Key companies operating in the hepatorenal syndrome treatment ecosystem vary in their strategic focus, ranging from developers concentrating on novel hemodynamic modulators and renal perfusion agents to firms optimizing formulations and delivery platforms that improve usability across care settings. Some organizations emphasize clinical differentiation through targeted clinical programs and real-world studies, while others prioritize broad access by focusing on cost-efficient manufacturing and supply chain resilience. Collaboration between specialty pharmaceutical developers, contract manufacturers, and providers has become increasingly important to accelerate development timelines and ensure scalability of manufacturing for parenteral and oral formulations.

Strategic alliances and licensing agreements are common pathways to expand geographic reach and share development risk. Companies that proactively invest in post-approval observational studies and educational initiatives with specialist societies are better positioned to influence clinical guidelines and prescribing practices. Moreover, firms that integrate patient support services and digital monitoring capabilities into their offerings can create differentiated value propositions by improving adherence and facilitating care continuity across inpatient and outpatient settings.

Action-oriented guidance to drive adoption and resilience through evidence-focused development, supply chain contingency planning, and segmented commercialization strategies

Industry leaders should prioritize an integrated approach that combines clinical evidence generation, supply chain resilience, and targeted stakeholder engagement to capture opportunities in hepatorenal syndrome treatment. First, aligning clinical development with endpoints that resonate with clinicians, payers, and regulatory bodies will facilitate faster uptake and reimbursement discussions. This includes designing pragmatic studies that reflect real-world care pathways and demonstrating outcomes that matter to health systems, such as reductions in intensive care utilization and improvements in renal function trajectories.

Second, supply chain and procurement strategies must be stress-tested against geopolitical and tariff-related scenarios, with contingency plans for alternative suppliers, nearshoring options, and inventory buffers. Third, commercial strategies should reflect segmentation priorities by tailoring messaging for branded versus generic positioning, emphasizing the operational advantages of intravenous or oral formulations as relevant, and addressing distinct needs of Type I and Type II patient cohorts. Finally, cultivating partnerships with hospitals, specialty clinics, and home care providers to embed support services and digital monitoring will enhance adherence and continuity of care, strengthening value propositions for payers and providers alike.

A rigorous multi-source qualitative methodology combining clinician input, regulatory review, and supply chain interviews to generate actionable strategic insights for stakeholders

The research methodology underpinning this analysis integrated a cross-functional evidence synthesis designed to capture clinical practice changes, stakeholder incentives, and operational realities. Primary inputs included consultations with practicing hepatologists, nephrologists, hospital pharmacists, and specialty clinic administrators to validate real-world pathways and adoption barriers. Supplementary inputs involved systematic reviews of peer-reviewed clinical literature, clinical trial registries, and regulatory guidance documents to triangulate therapeutic trends and evolving standards of care.

Operational insights were derived from interviews with supply chain and procurement professionals, as well as reviews of publicly available policy announcements and trade guidance to understand the implications of tariff and sourcing shifts. Where appropriate, the methodology emphasized qualitative synthesis and scenario analysis over quantitative forecasting to ensure the findings remain applicable across diverse market contexts. Throughout, the research team applied rigorous source validation and cross-stakeholder corroboration to ensure that insights are both actionable and reflective of current clinical and commercial realities.

Concluding synthesis emphasizing integrated evidence, operational resilience, and targeted engagement to convert clinical progress into sustainable patient access

In conclusion, effective navigation of the hepatorenal syndrome treatment landscape requires an integrated strategy that marries clinical differentiation with operational resilience and tailored market engagement. Clinical advances and evolving care models present opportunities to improve patient outcomes, but realizing those gains depends on deliberate evidence strategies that speak to clinicians and payers, as well as supply chain decisions that protect continuity of access. Companies that anticipate regional and policy-driven variations will be better positioned to deploy resilient commercialization plans that align with local practice and reimbursement realities.

Moving from insight to impact will require focused investment in targeted clinical programs, collaboration with care providers across hospitals and outpatient settings, and proactive management of procurement risks. By emphasizing measurable clinical benefits alongside practical adoption considerations, stakeholders can build persuasive value propositions that support sustainable access and ultimately improve care pathways for patients living with hepatorenal syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in noninvasive biomarkers for early detection of hepatorenal syndrome
  • 5.2. Emerging role of terlipressin in improving survival rates among advanced hepatorenal syndrome patients
  • 5.3. Integration of artificial intelligence algorithms in predicting hepatorenal syndrome onset and outcomes
  • 5.4. Clinical evaluation of selective endothelin receptor antagonists for managing renal dysfunction in HRS
  • 5.5. Growing adoption of albumin infusion protocols to prevent renal failure in cirrhosis related paracentesis
  • 5.6. Expansion of real world evidence studies on vasoconstrictor therapies in type 1 hepatorenal syndrome
  • 5.7. Innovations in point of care ultrasonography for monitoring renal hemodynamics in hepatorenal patients
  • 5.8. Regulatory landscape shifts and expedited approval pathways for novel HRS therapies boosting market momentum

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hepatorenal Syndrome Treatment Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Hepatorenal Syndrome Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Hepatorenal Syndrome Treatment Market, by Patient Severity

  • 10.1. Type I
  • 10.2. Type II

11. Hepatorenal Syndrome Treatment Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Hepatorenal Syndrome Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hepatorenal Syndrome Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hepatorenal Syndrome Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Mallinckrodt Pharmaceuticals plc
    • 15.3.2. Ferring Pharmaceuticals A/S
    • 15.3.3. Baxter International Inc.
    • 15.3.4. Grifols, S.A.
    • 15.3.5. Octapharma AG
    • 15.3.6. CSL Limited
    • 15.3.7. Kedrion S.p.A.
    • 15.3.8. LFB Group
    • 15.3.9. B. Braun Melsungen AG
    • 15.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 168. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 169. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 198. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 199. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 208. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 209. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 306. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 307.